Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Quality of Life Research
Published in: Quality of Life Research 5/2022

Open Access 01-05-2022 | Affective Disorder

The impact of poor medication knowledge on health-related quality of life in people with Parkinson’s disease: a mediation analysis

Authors: Hannah M. Zipprich, Sarah Mendorf, Aline Schönenberg, Tino Prell

Published in: Quality of Life Research | Issue 5/2022

Login to get access

Abstract

Purpose

This study aimed to determine how limited medication knowledge as one aspect of health literacy contributes to poorer health-related quality of life (HRQoL) in people with Parkinson’s disease (PD).

Methods

Demographical data, PD-specific data (MDS-Unified Parkinson’s Disease-Rating Scale, Nonmotor symptom scale), and data about depressive symptoms (Beck’s depression inventory), cognition (Montreal cognitive assessment), HRQoL (Short-Form Health Questionnaire-36, SF-36), and medication knowledge (names, time of taking, indication, dosage) were assessed in 193 patients with PD. Multivariate analysis of variance (MANOVA), multivariate analysis of covariance, and mediation analyses were used to study the relationship between medication knowledge and HRQoL in combination with different mediators and covariates.

Results

Overall, 43.5% patients showed deficits in at least one of the 4 knowledge items, which was associated with higher age, number of medications per day and depression level, and poorer cognitive function, motor function, and lower education level. Using one-way MANOVA, we identified that medication knowledge significantly impacts physical functioning, social functioning, role limitations due to physical problems, and role limitations due to emotional problems. Mediation models using age, education level, and gender as covariates showed that the relationship between knowledge and SF-36 domains was fully mediated by Beck’s Depression Inventory but not by Montreal Cognitive Assessment.

Conclusions

Patients who expressed unawareness of their medication did not necessarily have cognitive deficits; however, depressive symptoms may instead be present. This concomitant depressive symptomatology is crucial in explaining the contribution of nonadherence and decreased medication knowledge to poor quality of life.
Appendix
Available only for authorised users
Literature
1.
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017). Non-motor features of Parkinson disease. Nature Reviews Neuroscience, 18(7), 435–450.PubMed
2.
Schuepbach, W. M. M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., et al. (2013). Neurostimulation for Parkinson’s disease with early motor complications. New England Journal of Medicine, 368(7), 610–622.
3.
Wood-Dauphinee, S. (1999). Assessing quality of life in clinical research: From where have we come and where are we going? Journal of Clinical Epidemiology, 52(4), 355–363.PubMed
4.
5.
Grosset, D., Antonini, A., Canesi, M., Pezzoli, G., Lees, A., Shaw, K., et al. (2009). Adherence to antiparkinson medication in a multicenter European study. Movement Disorders: Official Journal of the Movement Disorder Society., 24(6), 826–832.
6.
Mendorf, S., Witte, O. W., Grosskreutz, J., Zipprich, H. M., & Prell, T. (2020). What Predicts different kinds of nonadherent behavior in elderly people with Parkinson’s disease? Frontiers Medicine (Lausanne), 7, 103.
7.
Mendorf, S., Witte, O. W., Zipprich, H., & Prell, T. (2020). Association Between Nonmotor Symptoms and Nonadherence to Medication in Parkinson’s Disease. Frontiers Neurology, 11, 551696.
8.
Straka, I., Minár, M., Gažová, A., Valkovič, P., & Kyselovič, J. (2018). Clinical aspects of adherence to pharmacotherapy in Parkinson disease: A PRISMA-compliant systematic review. Medicine, 97(23), e10962.PubMedPubMedCentral
9.
Shin, J. Y., & Habermann, B. (2016). Medication adherence in people with Parkinson disease. Journal of Neuroscience Nursing, 48(4), 185–194.
10.
Yap, A. F., Thirumoorthy, T., & Kwan, Y. H. (2016). Systematic review of the barriers affecting medication adherence in older adults. Geriatrics & Gerontology International, 16(10), 1093–1101.
11.
WHO. (2003). Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization.
12.
Grosset, K. A., Bone, I., & Grosset, D. G. (2005). Suboptimal medication adherence in Parkinson’s disease. Movement Disorders: Official Journal of the Movement Disorder Society, 20(11), 1502–1507.
13.
Daley, D. J., Myint, P. K., Gray, R. J., & Deane, K. H. (2012). Systematic review on factors associated with medication non-adherence in Parkinson’s disease. Parkinsonism & Related Disorders, 18(10), 1053–1061.
14.
Malek, N., & Grosset, D. G. (2015). Medication adherence in patients with Parkinson’s disease. CNS Drugs, 29(1), 47–53.PubMed
15.
Choi, S. K., Rose, I. D., & Friedman, D. B. (2018). How is literacy being defined and measured in dementia research? A Scoping Review. Gerontology and Geriatric Medicine, 4, 2333721418812246.PubMedPubMedCentral
16.
Marks, J. R., Schectman, J. M., Groninger, H., & Plews-Ogan, M. L. (2010). The association of health literacy and socio-demographic factors with medication knowledge. Patient Education and Counseling., 78(3), 372–376.PubMed
17.
Valldeoriola, F., Coronell, C., Pont, C., Buongiorno, M. T., Camara, A., Gaig, C., et al. (2011). Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson’s disease: The ADHESON study. European Journal of Neurology, 18(7), 980–987.PubMed
18.
Lindquist, L. A., Go, L., Fleisher, J., Jain, N., Friesema, E., & Baker, D. W. (2012). Relationship of health literacy to intentional and unintentional non-adherence of hospital discharge medications. Journal of General Internal Medicine, 27(2), 173–178.PubMed
19.
Ostini, R., & Kairuz, T. (2014). Investigating the association between health literacy and non-adherence. International Journal of Clinical Pharmacy, 36(1), 36–44.PubMed
20.
Agh, T., Domotor, P., Bartfai, Z., Inotai, A., Fujsz, E., & Meszaros, A. (2015). Relationship between medication adherence and health-related quality of life in subjects with COPD: A systematic review. Respiratory Care, 60(2), 297–303.PubMed
21.
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., et al. (2005). The Montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society., 53(4), 695–699.PubMed
22.
Kim, H. M., Nazor, C., Zabetian, C. P., Quinn, J. F., Chung, K. A., Hiller, A. L., et al. (2019). Prediction of cognitive progression in Parkinson’s disease using three cognitive screening measures. Clinical Parkinsonism & Related Disorders., 1, 91–97.
23.
Wang, Y. P., & Gorenstein, C. (2013). Psychometric properties of the beck depression inventory-II: A comprehensive review. Brazilia Journal of Psychiatry, 35(4), 416–431.
24.
Visser, M., Leentjens, A. F., Marinus, J., Stiggelbout, A. M., & van Hilten, J. J. (2006). Reliability and validity of the Beck depression inventory in patients with Parkinson’s disease. Movement Disorders, 21(5), 668–672.PubMed
25.
Martinez-Martin, P., Rodriguez-Blazquez, C., Alvarez-Sanchez, M., Arakaki, T., Bergareche-Yarza, A., Chade, A., et al. (2013). Expanded and independent validation of the movement disorder society-unified Parkinson’s disease rating scale (MDS-UPDRS). Journal of Neurology, 260(1), 228–236.PubMed
26.
Romenets, S. R., Wolfson, C., Galatas, C., Pelletier, A., Altman, R., Wadup, L., et al. (2012). Validation of the non-motor symptoms questionnaire (NMS-Quest). Parkinsonism & Related Disorders, 18(1), 54–58.
27.
Hagell, P., Törnqvist, A. L., & Hobart, J. (2008). Testing the SF-36 in Parkinson’s disease. Journal of Neurology, 255(2), 246–254.PubMed
28.
Rubenstein, L. M., Voelker, M. D., Chrischilles, E. A., Glenn, D. C., Wallace, R. B., & Rodnitzky, R. L. (1998). The usefulness of the functional status questionnaire and medical outcomes study short form in Parkinson’s disease research. Quality of Life Research, 7(4), 279–290.PubMed
29.
Martinez-Martin, P., Jeukens-Visser, M., Lyons, K. E., Rodriguez-Blazquez, C., Selai, C., Siderowf, A., et al. (2011). Health-related quality-of-life scales in Parkinson’s disease: Critique and recommendations. Movement Disorders: Official Journal of the Movement Disorder Society., 26(13), 2371–2380.
30.
Prell, T., Grosskreutz, J., Mendorf, S., Witte, O. W., & Kunze, A. (2019). Data on adherence to medication in neurological patients using the German Stendal Adherence to Medication Score (SAMS). Data Brief, 23, 103855.PubMedPubMedCentral
31.
Prell, T., Grosskreutz, J., Mendorf, S., Franke, G. H., Witte, O. W., & Kunze, A. (2019). Clusters of non-adherence to medication in neurological patients. Research in Social & Administrative Pharmacy: RSAP, 15(12), 1419–1424.
32.
33.
Liu, J., & Ulrich, C. (2016). Mediation analysis in nursing research: A methodological review. Contemporary Nurse, 52(6), 643–656.PubMed
34.
Hayes, A. F. (2018). Introduction to Mediation, Moderation, and Conditional Process Analysis, Methodology in the Social Sciences (2nd ed.). New York: Guilford Press.
35.
Rucker, D. D., Preacher, K. J., Tormala, Z. L., & Petty, R. E. (2011). Mediation analysis in social psychology: Current practices and new recommendations. Social and Personality Psychology Compass, 5(6), 359–371.
36.
Zhao, X. L., Lynch, J. G., Jr., & Chen, Q. (2010). Reconsidering Baron and Kenny: Myths and truths about mediation analysis. Journal of Consumer Research, 37(2), 197–206.
37.
Terwee, C. B., Bot, S. D., de Boer, M. R., van der Windt, D. A., Knol, D. L., Dekker, J., et al. (2007). Quality criteria were proposed for measurement properties of health status questionnaires. Journal of Clinical Epidemiology, 60(1), 34–42.PubMed
38.
Posthouwer, D., Plug, I., van der Bom, J., Fischer, K., Rosendaal, F., & Mauser-Bunschoten, E. (2005). Hepatitis C and health-related quality of life among patients with hemophilia. Haematologica, 90, 846–850.PubMed
39.
Schrag, A., Jahanshahi, M., & Quinn, N. (2000). What contributes to quality of life in patients with Parkinson’s disease? Journal of Neurology, Neurosurgery, and Psychiatry, 69(3), 308–312.PubMedPubMedCentral
40.
Zhao, N., Yang, Y., Zhang, L., Zhang, Q., Balbuena, L., Ungvari, G. S., et al. (2021). Quality of life in Parkinson’s disease: A systematic review and meta-analysis of comparative studies. CNS Neuroscience & Therapeutics, 27(3), 270–279.
41.
Wolf, M. S., Gazmararian, J. A., & Baker, D. W. (2005). Health literacy and functional health status among older adults. Archives of Internal Medicine, 165(17), 1946–1952.PubMed
42.
Gazmararian, J., Baker, D., Parker, R., & Blazer, D. G. (2000). A multivariate analysis of factors associated with depression: Evaluating the role of health literacy as a potential contributor. Archives of Internal Medicine, 160(21), 3307–3314.PubMed
43.
Kirsch-Darrow, L., Marsiske, M., Okun, M. S., Bauer, R., & Bowers, D. (2011). Apathy and depression: Separate factors in Parkinson’s disease. Journal of the International Neuropsychological Society, 17(6), 1058–1066.PubMedPubMedCentral
44.
Szymkowicz, S. M., Dotson, V. M., Jones, J. D., Okun, M. S., & Bowers, D. (2018). Symptom dimensions of depression and apathy and their relationship with cognition in Parkinson’s disease. Journal of the International Neuropsychological Society, 24(3), 269–282.PubMed
45.
Butterfield, L. C., Cimino, C. R., Oelke, L. E., Hauser, R. A., & Sanchez-Ramos, J. (2010). The independent influence of apathy and depression on cognitive functioning in Parkinson’s disease. Neuropsychology, 24(6), 721–730.PubMed
46.
Marsh, L. (2013). Depression and Parkinson’s disease: current knowledge. Current Neurology and Neuroscience Reports, 13(12), 409.PubMedPubMedCentral
47.
Smith, D., Lovell, J., Weller, C., Kennedy, B., Winbolt, M., Young, C., et al. (2017). A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PLoS ONE, 12(2), e0170651.PubMedPubMedCentral
48.
Rohde, D., Merriman, N. A., Doyle, F., Bennett, K., Williams, D., & Hickey, A. (2017). Does cognitive impairment impact adherence? A systematic review and meta-analysis of the association between cognitive impairment and medication non-adherence in stroke. PLoS ONE, 12(12), e0189339.PubMedPubMedCentral
49.
Mendorf, S., Witte, O. W., Grosskreutz, J., Zipprich, H. M., & Prell, T. (2020). What predicts different kinds of nonadherent behavior in elderly people with Parkinson’s disease? Frontiers in Medicine, 7, 103.PubMedPubMedCentral
50.
Kim, J., Kim, J. M., Yun, J., & Jeon, B. (2013). Use of the Pill Questionnaire to detect cognitive deficits and assess their impact on daily life in patients with Parkinson’s disease. Neurology Asia, 18, 369–375.
51.
Prell, T., Teschner, U., Witte, O. W., & Kunze, A. (2020). Current and desired quality of life in people with parkinson’s disease: The calman gap increases with depression. Journal of Clinical Medicine, 9(5), 1496.PubMedCentral
52.
Tosin, M. H. S., Stebbins, G. T., Goetz, C. G., Santana, R. F., Leite, M. A. A., & Oliveira, B. G. R. B. (2020). Measuring medication adherence in Parkinson’s disease: a systematic review of contributing components in rating scales. Movement Disorders Clinical Practice, 7(6), 607–615.PubMedPubMedCentral
53.
Bunevicius, A. (2017). Reliability and validity of the SF-36 Health Survey Questionnaire in patients with brain tumors: A cross-sectional study. Health and Quality of Life Outcomes, 15(1), 92.PubMedPubMedCentral
54.
Pekmezovic, T., Popovic, A., Tepavcevic, D. K., Gazibara, T., & Paunic, M. (2011). Factors associated with health-related quality of life among Belgrade University students. Quality of Life Research, 20(3), 391–397.PubMed
Metadata
Title
The impact of poor medication knowledge on health-related quality of life in people with Parkinson’s disease: a mediation analysis
Authors
Hannah M. Zipprich
Sarah Mendorf
Aline Schönenberg
Tino Prell
Publication date
01-05-2022
Publisher
Springer International Publishing
Published in
Quality of Life Research / Issue 5/2022
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-021-03024-8

Other articles of this Issue 5/2022

Quality of Life Research 5/2022 Go to the issue

OriginalPaper

“I don’t take for granted that I am doing well today”: a mixed methods study on well-being, impact of cancer, and supportive needs in long-term childhood cancer survivors

OriginalPaper

Validation and comparison of five preference-based measures among age-related macular degeneration patients: evidence from mainland China

OriginalPaper

Mapping the Haem-A-QoL to the EQ-5D-5L in patients with hemophilia

OriginalPaper

The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the ‘GO-UP’ study

OriginalPaper

Is malnutrition a determining factor of health-related quality of life in hemodialysis patients? A cross-sectional design examining relationships with a comprehensive assessment of nutritional status

Review

Patient-reported outcome measures in Arabic-speaking populations: a systematic review